ストックスクリーナーアプリを入手
34.55
1.77%
0.60
アフターアワーズ：
34.40
-0.15
-0.43%
Apogee Therapeutics Inc (APGE) 最新ニュース
(APGE) Trading Report - Stock Traders Daily
Interesting APGE Put And Call Options For October 17th - Nasdaq
Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month LowHere's What Happened - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Down 7.1%Here's Why - MarketBeat
Apogee Therapeutics' (APGE) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $608,700.00 in Stock - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 7.1% – What’s Next? - Defense World
Apogee Therapeutics Inc (APGE) presents a great opportunity, but the stock is slightly undervalued - US Post News
(APGE) Trading Signals - Stock Traders Daily
Apogee Therapeutics' chief medical officer sells $143,228 in stock - MSN
Apogee Therapeutics’ (APGE) Buy Rating Reaffirmed at Guggenheim - Defense World
Insider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 3,520 Shares of Stock - MarketBeat
Apogee Therapeutics CEO Michael Henderson sells $608,700 in stock - MSN
Apogee Therapeutics' chief medical officer sells $143,228 in stock By Investing.com - Investing.com Australia
Apogee Therapeutics Inc (NASDAQ: APGE) Recovered 16.57% From The 52-Week Low, And Now It’s -12.32% YTD – This Is What You Do Now – Marketing Sentinel - Marketing Sentinel
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,520 Shares - Armenian Reporter
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of "Buy" by Analysts - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average Target Price from Brokerages - Defense World
Market Watch: Apogee Therapeutics Inc (APGE)’s Noteworthy Drop, Closing at 40.37 - The Dwinnex
Should investors be concerned about Apogee Therapeutics Inc (APGE)? - US Post News
Apogee Therapeutics Advances APG777 in Key Phase 2 Trial - TipRanks
Apogee Therapeutics Announces First Patient Dosed in Part B - GlobeNewswire
Clinical Trial Breakthrough: Apogee's Novel Eczema Drug Draws Record Patient Interest - StockTitan
SG Americas Securities LLC Has $448,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 - Insider Monkey
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference - Marketscreener.com
Apogee's Management Reveals Latest Developments at Major Biotech Conference - StockTitan
Apogee Therapeutics: No Clinical Efficacy Data, Strong Competition, High Market Cap - Seeking Alpha
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by JPMorgan Chase & Co. - Defense World
(APGE) Investment Report - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 4.6%Should You Sell? - MarketBeat
Comparing Apogee Therapeutics (NASDAQ:APGE) and BioCardia (NASDAQ:BCDA) - Defense World
CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus.com
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $89.71 - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares - MarketBeat
Apogee Therapeutics CEO sells shares worth $732,692 By Investing.com - Investing.com Australia
Apogee Therapeutics CEO sells shares worth $732,692 - Investing.com India
Apogee Therapeutics (NASDAQ:APGE) Shares Down 9.1%What's Next? - MarketBeat
Trend Tracker for (APGE) - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):